microsatellite instability-high colorectal cancer
GPTKB entity
Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
colorectal cancer subtype
|
| gptkbp:abbreviation |
MSI-H colorectal cancer
|
| gptkbp:associatedWith |
gptkb:Lynch_syndrome
defective DNA mismatch repair MLH1 gene mutation MSH2 gene mutation MSH6 gene mutation PMS2 gene mutation |
| gptkbp:characterizedBy |
high level of microsatellite instability
|
| gptkbp:commonIn |
right-sided colon cancer
|
| gptkbp:guidanceSystem |
NCCN guidelines recommend MSI testing for all colorectal cancers
|
| gptkbp:hasBiomarker |
microsatellite instability
deficient mismatch repair |
| gptkbp:hasEpidemiology |
more common in younger patients with Lynch syndrome
more common in older patients with sporadic MLH1 methylation |
| gptkbp:hasScreeningTest |
PCR-based microsatellite instability testing
immunohistochemistry for mismatch repair proteins |
| https://www.w3.org/2000/01/rdf-schema#label |
microsatellite instability-high colorectal cancer
|
| gptkbp:incidence |
about 15% of colorectal cancers
|
| gptkbp:lessLikelyToHave |
gptkb:KRAS_mutation
BRAF mutation |
| gptkbp:pathology |
tumor-infiltrating lymphocytes
mucinous histology poor differentiation |
| gptkbp:prognosis |
better prognosis than microsatellite stable colorectal cancer
|
| gptkbp:significance |
predicts lack of benefit from 5-FU chemotherapy
predicts response to immunotherapy |
| gptkbp:treatment |
gptkb:pembrolizumab
gptkb:ipilimumab gptkb:nivolumab immune checkpoint inhibitors |
| gptkbp:bfsParent |
gptkb:ipilimumab
|
| gptkbp:bfsLayer |
7
|